The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, said on 23 February 2021 that Mexico, the first country in North America to approve Russia's Sputnik V COVID-19 vaccine, has received its first batch of the vaccine, CNN reported on Tuesday.
In a statement, the RDIF said: "On 3 February 2021, the Federal Commission for the Protection against Sanitary Risk of Mexico (COFEPRIS) approved Sputnik V under the emergency use authorisation procedure without additional clinical trials in the country."
Kirill Dmitriev, CEO of the RDIF, said: "it is a significant breakthrough in Russia's efforts to fight COVID-19 and clearly shows that saving lives is above politics."
According to figures from the RDIF, which oversees global distribution and sales of the vaccine, Russia's Sputnik V COVID-19 vaccine has now been approved for use in more than 30 countries and is one of the world's most pre-ordered vaccines, with at least 50 countries, from Argentina to the Philippines, ordering nearly 2.5 billion doses so far.
A tally by Johns Hopkins University has revealed that Mexico has the third highest death toll in the world, behind the US and Brazil, with more than 180,000 deaths.
EpiVax introduces AI-enhanced models for immunogenicity prediction
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
4basebio announces strategic collaboration with Genezen
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Piramal Pharma acquires controlling stake in Yapan Bio
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070